raltegravir (Isentress) — Competitive Intelligence Brief

raltegravir (Isentress) (raltegravir (Isentress)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Integrase strand transfer inhibitor (INSTI). Area: Infectious Disease.

phase 3 Integrase strand transfer inhibitor (INSTI) HIV integrase Infectious Disease Small molecule

Target snapshot

raltegravir (Isentress) (raltegravir (Isentress)) — Groupe d'Etude sur le Risque d'Exposition des Soignants aux Agents Infectieux. Raltegravir inhibits HIV integrase, preventing the virus from integrating its genetic material into the host cell's DNA.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
raltegravir (Isentress) TARGET	raltegravir (Isentress)	Groupe d'Etude sur le Risque d'Exposition des Soignants aux Agents Infectieux	phase 3	Integrase strand transfer inhibitor (INSTI)	HIV integrase
Raltegravir and Abacavir/Lamivudine	Raltegravir and Abacavir/Lamivudine	Denver Infectious Disease Consultants, PLLC	marketed	Antiretroviral combination (INSTI + NRTI)	HIV integrase, HIV reverse transcriptase
Raltegravir; Abacavir/Lamivudine	Raltegravir; Abacavir/Lamivudine	Central Institute of Epidemiology, Moscow, Russia	marketed	Antiretroviral combination therapy (integrase inhibitor + nucleoside reverse transcriptase inhibitors)	HIV integrase; HIV reverse transcriptase
Antiretroviral/Anti HIV	Antiretroviral/Anti HIV	MSD Pharmaceuticals LLC	marketed	Antiretroviral agent (multiple classes: NRTI, NNRTI, PI, INSTI, entry inhibitor)	HIV reverse transcriptase, HIV protease, HIV integrase, CCR5, or CXCR4 (depending on specific agent)
Raltegravir, lopinavir, ritonavir	Raltegravir, lopinavir, ritonavir	Allina Health System	marketed	Antiretroviral combination therapy (integrase inhibitor + protease inhibitors)	HIV integrase, HIV protease
Raltegravir and Atazanavir	Raltegravir and Atazanavir	Peter J. Ruane, M.D., Inc.	marketed	Antiretroviral combination (integrase inhibitor + protease inhibitor)	HIV integrase and HIV protease
Raltegravir and truvada	Raltegravir and truvada	The University of Texas Health Science Center, Houston	marketed	Antiretroviral combination (INSTI + NRTI)	HIV integrase; HIV reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Integrase strand transfer inhibitor (INSTI) class)

1. ViiV Healthcare · 12 drugs in this class
2. National Institute of Allergy and Infectious Diseases (NIAID) · 5 drugs in this class
3. Merck Sharp & Dohme LLC · 5 drugs in this class
4. Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal · 1 drug in this class
5. Germans Trias i Pujol Hospital · 1 drug in this class
6. Groupe d'Etude sur le Risque d'Exposition des Soignants aux Agents Infectieux · 1 drug in this class
7. ANRS, Emerging Infectious Diseases · 1 drug in this class
8. Massachusetts General Hospital · 1 drug in this class
9. University of Colorado, Denver · 1 drug in this class
10. MU-JHU CARE · 1 drug in this class